Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial

BACKGROUND: The effectiveness of gemcitabine plus capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer has been evaluated in the ESPAC-4 trial. We aimed to assess the cost-effectiveness of these adjuvant regimens on resected pancreatic cancer. METHODS: A Markov model was...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jiaxing, Liao, Weiting, Zhou, Jing, Zhang, Pengfei, Wen, Feng, Wang, Xinyuan, Zhang, Mengxi, Zhou, Kexun, Wu, Qiuji, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173491/
https://www.ncbi.nlm.nih.gov/pubmed/30323662
http://dx.doi.org/10.2147/CMAR.S172704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173491/
https://www.ncbi.nlm.nih.gov/pubmed/30323662
http://dx.doi.org/10.2147/CMAR.S172704

Ejemplares similares